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1. 
PREFACE 
Nucleosides, the nitrogen glycosides of purines 
and pyrimidines and their phosphate esters, known 
as nucleotides are vital components of all living 
cells and are intimately involved in many biological 
processes, such as protein synthesis, storage and 
transformation of genetic information, oxidation, 
reduction and electron transport processes. 
Living cells contain a variety of low molecular 
weight nucleotides, which have important roles as 
reaction intermediates in the complex integrated chemi-
cal reactions of the cell. They synthesize their requ-
irement of purine and pyrimidine nucleotides from 
amino acids. 
Modification of heterocyclic and/or sugar moiet-
ies of purine nucleosides affords modified nucleosides 
which may either inhibit or act as a coijnpetitive sub-
I 
strate of soiiie important enzymes and thus exhibit 
a variety of biological activities. 
In the thesis the synthetic analogues of bio-
logically active nucleosides and their biological 
evaluation is described. It is divided into two chapters, 
The first chapter is a general review and deals 
1 1 . 
with acyclic nucleosides of biological interest 
The second chapter deals with the synthesis 
of acyclic nucleosides of 4-substituted pyrazolo[3/4-
d]pyrimidine and their biological activity. 
X X X . 
ABBREVIATIONS 
ATP : Adenosine triphosphate 
AMP : Adenosine monophosphate 
IMP : Inosine monophosphate 
RNA : Ribonucleic acid 
DNA : Deoxyribonucleic acid 
HSV : Herpes simplex virus 
GMP : Guanosine monophosphate 
PRPP : Phospho ribosyl py rophosphte 
Ara-A : Adenosine arabinoside 
CHAPTER - I 
Acyclic Nucleosides of Biological Interest 
-1-
1.1 INTRODUCTION 
The nitrogen heterocyclic molecules are of consi-
derable interest to chemists/ biochemists and medicinal 
chemists and provide interesting problems for synthesis 
and to study the mechanism of biological processes 
at molecular level. They also provide a 'Lead compound' 
for designing new drugs for a variety of human ailments. 
Several nitrogen heterocycles are elaborated by both 
animal and plant cells. Of these purine and pyrimidine 
nucleosides and nucleotides are of considerable interest. 
The term "nucleoside" introduced by Levene and 
Jacobs in 1909/ was originally used for carbohydrate 
derivatives of purine and/or pyrimidine/ isolated from 
alkaline hydrolysates of yeast ribonucleic acid (RNA) 
and enzymetic digestion of thymus deoxyribonucleic 
2 
acid (DNA) . However, the current definition of nucleo-
sides is very broad. It includes all those compounds 
in which a nitrogen heterocyclic moiety is linked to 
a glycon moiety. The heterocyclic moiety may be a subst-
ituted purine/ modified purine such as pyrazolo pyri-
midine/ pyrrolo-pyrimidine/ aza and deaza purines/ 
substituted pyrmidine and a modified pyrimidine base. 
The glycon moiety may be ribose/ deoxyribose or any 
other sugar/It can also be an alcohol and amino alcohols 
moiety. 
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1.2 TYPES OF NUCLEOSIDES 
Nucleosides can be broadly classified into N-
nucleosides (1) and C-nucleosides (2). In N-nucleosides, 
the anomeric carbon atom of sugar is attached to hetero-
cyclic moiety by C-N bond/ whereas in C-nucleoside/ 
the anomeric carbon atom of sugar is attached to hetero-
cyclic moiety by C-C single bond. 
HO HO—, 
H(l) OH H6 OH 
1 2 
The compound in which the glyconk moiety has 
a cyclic structure like ribose/ xylose/ arabinose etc. 
are called 'cyclic nucleosides' and the compounds in 
which an open chain structure constituted the glycone 
moiety/ called 'acyclo nucleosides'. 
1.3 BIOLOGICAL IMPORTANCE OF NUCLEOSIDES 
Nucleosides and nucleotides have attracted consi-
derable attention, not only because they are building 
blocks of nucleic acid DNA and RNA/ but also they are 
co-factors and allosteric effectors in many of the 
-3-
fundamental enzymic reactions. 
Excellent reviews dealing with various aspects 
of purine and pyrimidine nucleosides are available 
3-12 in literature . Analogues of natural purine and 
pyrimidine nucleosides have proved to be quite effective 
as antibacterial/ antiviral, anticancer and antitumor 
agents, due to their role as enzymes inhibitors and 
agonist/antagonists. > 
Adenosine (3), deoxyadenosine (4), guanosine 
(5), deoxyguanosine (6), cytidine (7), deoxycytidine 
(8), uridine (9) and thymidine (10) are the component 
of nucleic acid are given in Fig. 1. 
1.4 NATURALLY OCCURING MODIFIED NUCLEOSIDES 
A variety of modified nucleosides have been iso-
lated from plants and mammalian DNA. A numer of interest-
ing nucleosides that have been isolated from marine 
organisms are spongouridine (11), doridosine (12), 
3'-acetyl spongosine (13) and spongosine (14) are given 
in Fig. 2 . 
Another group of modified purine and pyrimidine 
nucleosides that have been isolated from microorganism, 
and exhibited antibiotic activity are called as "nucleo-
side antibiotics". Some of the nucleoside! antibiotics 
in which the heterocyclic moiety is modified are formycin 
(15), nebularin (16), cadeguamycin (17), toyocamycin. 
(18), bredenin (19), showdomycin (20) and pyrazomycin 
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N N 
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(21) are given in Fig3. The nucleoside antibiotics 
in which the glycon moiety is modified are psicofuramycin 
(22), cordycepin (3'-deoxyadenosin e) (23), 3'-amino-
3'-deoxyadenosine (24), 3 '-acetamido-3 '-deoxyadeno.sine 
(25), homocitrullyl amino adenosine (26), lysylaminoade-
nosine (27) and decoyinine (28) are given in Fig. 4. 
There are several nucleoside antibiotics in when 
both the heterocyclic and glycon moieties are modified. 
Example of these class of nucleoside are puromycin 
(29), 5'-deoxy-5'-iodotubercidin (30), amicetin (31) 
and plicacetin (32) are given in Fig. 5. 
1.5 SYNTHETIC MODIFIED NUCLEOSIDES 
The biological activity of a nucleoside can be 
modulated by making chemical modification in heterocyclic 
and/or carbohydrate moiety or by changing the configur-
ation of the hydroxyl function in sugar moiety. 
In recent years, several nucleosides have been 
obtained by replacing the normal sugar moieties such 
as D-ribose and D-deoxyribose by a variety of non-conven-
tional acyclic alcohols. The compounds of this type 
are termed as 'acyclic nucleosides', which exhibit 
high order of biological activities. Depending on the 
substituent in the heterocyclic moiety, acyclic nucleo-
side could be divided into two groups, the guanine 
and the adenine. 
-8-
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1.5.1 Guanosine Analogues 
In the nucleosides of this class D-ribose moiety 
13 
of the nucleoside is replaced by 2-hydroxy ethoxy methyl / 
amino acyl esters , 1,3-(dihydroxy-2-propoxy)methyl ~ / 
18 19 
4-hydroxybutyl , 3,4-dihydroxybutyl group 
1.5.2 Adenosine Analogues 
In this class of nucleosides the D-ribose moiety 
of the nucleoside is replaced by the aliphatic side 
20 
chain such as 2,3-dihydroxypropyl ; 2,3-dihydroxybut-
21 yl and 2/3-dihydroxybutanoic acid (as in the eritaden-
.22 ine) 
The guanine acyclic nucleosides are specifically 
cytomegalo • 4- u • -i • 13-19 
active against herpes simplex virus , 
virus ' and Epstein Barr virus , while the adenine 
acyclic nucleosides are S-adenosyl-L-homocystein hydrolase 
inhibitors or adenosin deaminase inhibitors. They show 
a wide spectrum of antiviral activities against DNA 
and RNA viruses including poxviridase (vaccinia)/ rhabdo-
viridase (rabies/ vericular stomatitis), paramyxoviridae 
(measles/ parainfluenza) and reoviridae (reo, rota). 
1.6 GUANOSINE NUCLEOSIDES ANALOGUES 
1.6.1 Hydroxy ethoxy methyl guanine (acyclovir) analogue 
Significant progress has been made in the deve-
lopment of antiviral chemotherapy ' ~ . A number of 
- 1 1 -
nucleosides effective against Herpes virus have been 
synthesized. Replacement of ribofuranosyl moiety of 
guanosine with 2-hydroxy ethoxy methyl moiety yielded 
9-{2-hydroxyethoxymethyl)guanine (acyclovir) (33)/ a 
potent antiviral drug. In acyclovir (33) the base -C(1')-
0-C(4')-C(5') fragment of guanosine (5) is present. 
HN 
2 ^N-^ "N 
HO -~! 
N 
OH OH 
5 
O 
HN 
33 
—-N 
H N ^ ^^ 
HO 
13 Schaeffer et^ aJ^  have reported the synthesis 
and antiherpes activities of acyclovir. It is a very 
potent inhibitor of herpes simplex virus type-1 (HSV-1), 
type-2 (HSV-2), varicella zoster virus (VZV) and cytome-
galo virus replication and produces little cytotoxicity 
in uninfected cells ' . Acyclovir is specifically 
phosphorylated to its 5'-monophosphate by herpes virus 
thymidine kinase, but not by cellular thymidine kin-
ase ' . Acyclovir triphosphate, synthesized by cellular 
kinase from monophosphate is more potent inhibitor 
of the virus. 
•12-
Several acyclovir analogues (34-42) have been 
synthesized and some of them exhibit good antiviral 
activity. 
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Since the compounds with guanine moiety (37-40) 
were found more potent than with adenine (42) or 2,6-
diamino purine moieties (41), several acyclonucleosides 
39 
with guanine moiety (43-48) were synthesized 
H^N 
HO-
43 
O 
HN 
" 2 ' ^ ^ . -
H 
fl 
6H 
46 
HN' 
HO-
-N HN 
H3C 
47 
H 
CH, 
48 
—N 
V ^N-^'-N'^ «2»^^N" > 
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Correlations with antiherpetic activity and enzy-
matic phosphorylation of various acyclovir analogues 
40 41 
have been studied by Keller et_ al_ and Kelley . It has 
been found that nucleosides although are phosphorylated 
but do not exhibit viral activity which suggest that 
phosphorylation catalysed by the thymidine kinase alone 
is not sufficient for inhibition of viral replications. 
Antiviral efficacy in HSV-1 keratitis in rabbit 
was found in compound (49). 
HN 
H^N 
RO 
•N-
N 
N-
4£, R=C0CH2NH2.HC1 
50/ C0CH(CH2)NH2.HC1 
_5]^  COCH2CH2NH2.HCI 
52 COCH2CH2COONa 
52 COCH2N2 
54 COCH(CH^)NHCOOCH^C^Hc 
55 COCH„CH_NHCOOCH^C-Hc 2 2 2 6 5 
56 COCH CH2COOH 
42 Vanderhaeghe and coworkers synthesized and 
evaluated the antiviral activity of compounds (49-56). 
A number of 8-substituted purine acyclonucleosides 
43 
were prepared by Robins et £l for antiviral/ antimeta-
bolic and cytotoxic properties. Among these the 57-
60 analogues exhibited significant activities. 
-15-
51_, 
5 8 , 
5 9 , 
6 0 , 
R = CH 
Br 
I 
NH 
Acyclovir analogues (61-64) were reported by 
44 Beauchamp et^  £l , with various heterocyclic moieties 
such as pyrazolo[3,4-d]pyrimidine (61), pyrrolo[2,3-
45 d^] pyrimidine (62) , benzoguanine (63), 8-azapurine 
(64), imidazole, triazole and isocytosine. 
"a^-^N- -N^ 
HO—, u^ 
0 
HN 
HO— 
N' N^-
61 62 
63 64 
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Comparative binding studies of acyclovir and 
nucleoside (64) with thymidine kinase had been reported. 
Synthesis of 6-deoxyacyclovir (65) as prodrug 
45 
was reported by Kreintsky et^ al_ . The deoxyacyclovir 
was found to be 18 times more water soluble than acyclovr. 
Furthermore/ the 6-deoxyacyclovir was readily oxidised 
to acyclovir by xanthine oxidase. Another acyclovir 
derivativatives 2/6-diamino-9-(2-hydroxyethoxy)methylpur-
46-48 ine (A 134U) (41) was studied as prodrug. A 134U 
(41) was converted into acyclovir by adenosine deaminase 
and four other minor metabolites 
1.6.2 9-(3/4-Dihydroxybutyl)guanine (DHBG)and analogue 
9-(3,4-Dihydroxybutyl)guanine (DHBG) (70) showed 
49 50 
significant antiperpes activity ' . DHBG was selectiv-
ely phosphorylated by HSV thymidine kinase. The (R)-
enantiomers (70-a) was found to inhibit viral multipli-
cation than the (S)-enanthiomers (70-b). DNA synthesis 
of herpes virus was selectively inhibited by (RS)-DHBG 
(70-c) in infected cells. Further the compounds was 
found to have low cellular toxicity. 
Antiviral activity of DHBG had also been compared 
51 52 
with other related acyclonucleosides . DHBG isomer (71) 
was found to have low order of antiviral activity. 
53 L-erythroisomer (72) was synthesized 'from L-arabinose 
-17-
65 
H 
«2^" 
H 
-N dehydro 
^ — 
0 . 
67 
genaseH^N N ^ 
aldehyde / oxidase aldehyde 
oxidase dehydro-
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NH, 
H2N 
Ha 
N N 
H. 
•^ N 
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66 68 
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which stereochemically represents the "bottom half" 
of the D-ribofuranose moiety. However, this compound 
did not show any activity against herpes and polioviruses, 
70 
(S)-DHBG 
OH 
NH, 
% 
N 
HO—J 
N 
y 
OH 
HOH C-
OH OH 
71 72 
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1.6.3 9-[(l/3-Dihydroxy-2-propoxy)methyl]guanine (DHPG) 
analogues 
Several analogues of acyclovir had been synthe-
sized. Some of these had shown high order of antiviral 
54—56 
activities . DHPG (73) is one of such nucleosides/ 
which had been found very promising 
DHPG (73) had similar activity of acyclovir against 
HSV-1 and HSV-2 In vitro. DHPG also inhibited cytomega-
lovirus and Epstein-Barr virus . Although two comp-
ounds acyclovir and DHPG had similar activity against 
HSV in vitro. A striking difference was that of DHPG 
exhibited higher activity i^ vivo against herpes enceph-
alitis and vaginites ~ . Mode of action of DHPG and 
acyclovir were similar. Both the compounds are phosphorr 
ylated by viral induced thymidine kinase and both select-
ively inhibit the virus DNA synthesis . Virus indu-
ced thymidine kinase first phosphorylated the DHPG 
to its monophosphate. It is subsequently phosphorylated 
by host cellular enzymes into its 5'-di and finally 
to its 5'-triphosphate derivative. Thus in contrast 
with acyclovir, DHPG seemed to be incorporated into 
DNA strands 
Various analogues of DHPG had been synthesised 
due to the significant ^n vivo antiviral activities. 
Lin and coworkers had reported the synthesis of amino 
analogues (74). The reason for the synthesis of (74) 
-20-
and its analogues was that the amino group is sterically 
and electronically similar to that of the hydroxyl 
group. Which may lead to the compound with high antiviral 
activities and low host cytotoxicity. Compound (74) 
/TO 
exhibited moderate antiviral activity 
H , N -%« 
HO 
HN 
T 
OH 
HO—I 
J 
73 
HN N 
"z^-^^N^ 
HO 
75 
_N 
N^^  
H2 21 
Thio analogues (75) of DHPG had also been synthe-
69 
sized by McGee £t^  al^  . The compound (75) exhibited 
comparable activity iji vitro to DHPG against HSV-1 
and human cytomagalovirus. 
-2-1 
70 Ogilvie et^  a]^ had synthesized the DHPG analogues 
(76-80) with an additional hydroxy methyl group on 
the acyclic side chain. This modification decreased 
the herpetic activity. Further side chain elongation 
71 
as in (81) had significantly reduced antiviral activity 
HSV-1/ HSV-2 and cytomegalovirus. Another DHPG analogues 
(RS)-9-(2;3-dihydroxy-l-propoxymethyl)guanine (82) 
72 73 
has been reported by both Lin and Lin and Ashton . (R)-
74 
and (S)-enantiomers had also been synthesized. The 
(S)-isomer (83) was found to be 10 to 25-fold more 
action than (R)-isomer (84) against HSV-1 and HSV-2 
in cell culture. 
HN 
HO. 
HO-
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HO-
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-22-
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1.7 ADENOSINE NUCLEOSIDE ANALOGUES 
1.7.1 9-(2-Hydroxyethoxymethyl)adenine analogues 
Schaeffer and coworkers ' had reported the 
synthesis and binding characteristics of adenosine 
deaminase inhibition activity of a number of Nq-alkyl 
substituted adenine analogues (85-91). 
R, 
Inhibition of Adenosine 
deaminase 
85^  
86 
88 
89 
9^ 
91 
NH, 
NHCH. 
NH, 
NHCH, 
NH, 
NHCH. 
HO(CH2)2 
HO(CH2)2 
HO(CH2)3 
HO(CH2)3 
HOCCH^)^ 
HOCCH^)^ 
Adenosine 
Compounds (85) and (87) were found to be most 
effective inhibitors and bound to the enzymes twice 
as tightly as adenosine (91). It was known that 5'-
deoxynucleosides of adenine do not undergo deamination 
with adenosine deaminase unless a properly positioned 
hydroxyl group is present at C-3' as in 9-(5'-deoxy-
-D-xylofuranosyl)adenine. This showed that 5'-hydroxyl 
group plays a role in the deamination reaction. Based 
77 
on this Schaeffer and coworkers prepared 9-(2-hydroxy 
ethoxymethyl)adenine (92), which contains the 5'-hydroxyl 
portion of adenosine (91). However the deoxy compound 
-24-
(93) did not show any substrate activity. 
NH, 
^ . ^ ^ 
HO—1 
•N 
NH, 
92 
NH, 
N 
S 
H3C 
N 
-0 
93 
-N 
y 
1.1.2 9-(2,3-Pihydroxypropyl)adenine (DHPA) analogues 
Antiviral activity of (S)-9-(2,3-dihydroxypropyl) 
78 
adenine (S-DHPA) had been reported by DeClercq et_ al 
(S)-DHPA inhibited several viruses including vaccinia/ 
HSV-1 and HSV-2, measles and vericular stomatitis. 
The racimic mixture (RS)-DHPA was as active as the 
(S)-enantiomers. Which (R)-isonier of DHPA was inactive. 
(S)-DHPA/ strongly inhibited deamination of adenosine 
and ara-A by adenosine deaminase. It is suggested that 
nucleoside may inhibit S-adenosyl-L-homocyateine hydro-
lase . Schaeffer and coworkers had reported that race-
mic DHPA (94) is a weak inhibitor of adenosine deaminase. 
80 
Holy had synthesised the (R)- and (S)-enantiomers 
76 78 
of (94) and had also prepared ' several other purine 
-25-
derivatives. However ncJne of the compounds (95-102) 
showed any significant antiviral activity. 
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DHPA analogues having different I aglycons such 
as pyrrolo[2,3-d]pYrimidine (103)®"'"'^ ,^ triazolo[4,5-d] 
83 pyriitiidine (104) did not show any significant activjLty. 
The nucleoside (105) showed antiviral activity against 
vaccimia virus and inhibited S-adenosyl homocystein 
hydrolase 
NH, 
N 
^ 
N 
^ N / ^ N - - " 
OH 
104 
NH, 
N 
%/S^ 
OH OH 
105 
N 
1.7.3 Erythro-9-[2-hydroxy-3-nonyl]adenine (EHNA)analogues 
Schaeffer and coworkers had extensively studied 
the substrate binding characteristics of adenosine 
deaminase and found that the binding area for the 9-
84 
substituents is a large hydrophobic region / a hydroxyl 
85 binding site and a specific methyl binding region . In 
the case of 9-(l-hydroxy-2-alkyl)adenine/ the preferred 
chiral centre for enzyme inhibitor complex formation 
has the (R)-configuration , while in the case of 9-
-27-
(2-hydroxypropyl)adenine/ the chiral centre with (S)-
85 
configuration is bound more tightly to the enzyme 
Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) (106) prep-
ared on the basis of above studies was most potent 
inhibitor 
NH, 
N N 
% , > \ N' 
^6»i; 
-OH 
EHNA 
CU. 106 
Structurally related to EHNA/ erythro-9-(2-hydroxy 
-3-nonyl)hypoxanthine (NPT 15392) [ a mixture of (107) 
and (108)] had been reported to have immunopotentiating 
88/89 
activity 
immune response 
. The compound enhances T-cell dependent 
90 
0 
HN 
^ N x - ^ J 
^6^13 
CH^ (2S, 3R) 
^6"l3' 
OH 
CH^ (2R, 35) 
107 (+) erythro 108 (-) erythro 
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In view of the significant biological activity 
of EHNA and its hypoxanthine analogues (NPT 15392), 
91 Grifantini and coworkers synthesized deaza-analogues 
of EHNA in order to study the structural requirements 
of EHNA as an inhibitor of adenosine deaminase. 3-Deaza-
EHNA (109) was found to have an inhibitory activity. 
While 1-deaza-EHNA (110) was found to have less inhibit-
ory activity. 
NH^ 
N N 
"^6^13 
-OH 
CH, 
109 
^ - ^ ^ 
•^6"l3 
-OH 
CH, 
110 
1.7.4 Eritadenine analogues 
Erit-tidenine (111)/ a hypolipidemic agent iso-
lated from Japanese edible mushroom Shiitake (Leutinus 
edodes) had been characterized as 2(R)/ 3(R)-dihydroxy-
4-(9-adenyl)butyric acid. Deoxy eritadenine and 9-carboxy 
propyl adenine had also been isolated from the same 
92-94 organisms 
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N N 
•N' 
HO-
HO-
(i02H 
111 Eritadenine 
95 Takeyama and coworkers had synthesized more 
than 100 derivatives of eritadenine which showed hypoch-
olesterolemic activities. From the structural activity 
relationship, the carboxylic acid derivatives was f,ound 
most active with short chain mono hydroxy alcohols. 
These compounds were found 50 times more active than 
eritadenine in lowering the serum cholesterol in rate. 
The isoamyl esters of eritadenine inhibits protein 
kinase by acting as a competitive inhibitor of ATP, 
96 
which indicates that these esters act at the receptor 
site. Holy and coworkers showed that eritadenine and 
its analogues as S-adenosyl-L-homocystein hydrolase 
97-104 inhibitors and as antiviral agents . So eritadenine 
and its derivatives inhibits S-adenosyl-L-homocysteine 
hydrolase. 
Since the methyl esters of D-eritadenine is more 
potent as an antiviral agent than the parent compound. 
105 De Clercq and Holy studied various alkyl esters 
of adenyl-9-yl-2-hydroxypropanoic acid (112). 
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NH, 
N 
^ N . 
HO" 
CiO^ R 
112a 
W 
•OH 
CO^R 
112b 
These esters showed broad inhibitory activity 
against vesicular stomatitis/ vaccinia/ reo/ parainfl-
uenza and measles viruses and they are nontoxic to 
the host cell at antivirally active concentrations. 
Holy et aJ^  studied a number of -carboxyl 
alkyl derivatives of adenine and other purine bases 
(113-120) for their inhibitory effects on rat liver 
S-adenosyl-L-homocystein hydrolase and their antiviral 
activity. 
«1 
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CHAPTER - II 
Synthesis of acyclic nucleosides of 4-substituted 
pyrazolo[3/4-d^]pyrimidine and their biological activity 
-41-
2.1 INTRODUCTION 
Adenosine (1)/ a well known naturally occurring 
1 2 
nucleoside/ is an effective coronary vasodialator ' 
3 
and inhibitor of platelets thrombi . It is believed 
that/ when cells are injured/ some of their adenosine 
triphosphate (ATP) breaks down to adenosin diphosphate 
4 
(ADP)/ which initiate the aggregation of blood platelets . 
Adenosine diphosphate on further dephosphorylation 
by plasma enzymes ' produces adenosine monophosphate 
7 (AMP) or adenosine/ which exerts its inhibitory action 
Q 
on platelets aggregation . The analogs of adenosine 
have longer duration of action as compared to adeno-
. 9,10 
sine 
The replacement of ring carbon or nitrogen 
of purine (2) by a nitrogen or carbon atom gives aza 
or deaza purines (3/4) ring systems respectively/ whereas/ 
interchange of nitrogen at position-7 with carbon at 
position-8 of purine system (2) affords pyrazolo[3,4-
d]pyrimidine (5). A number of deaza and azapurine nucleo-
sides have been synthesized as potential antitumor 
^ «-• • 1 4. 11/12 and antiviral agents 
Pyrazolo [3/4-d^ ] pyrimidine nucleosides have 
received considerable attention due to their wide spect-
13 
rum of biological activities. Allopurinol (pyrazolo 
- 4 2 -
s 
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[3/4-d]pYrimidin-4-one) an analogue of hypoxanthine 
(7) is an inhibitor of purine catabolic enzyme/ xanthine 
14 
oxidase and iu used for the treatment of hyperurece-
1 c 1 c 
mia responsible for gout . 4-Amino pyrazolo[3#4-
d^Jpyrimidinriboside (8) an analogue of adenosine is 
17-22 
action against a number of species of Leishmania 
Several varities of nucleosides have been synth-
sized in recent years. Some of these nucleosides have 
shown significant anticancer, antiparasitic and antiviral 
activities. Few of these are being used as drugs. One 
of the drawbacks of the biologically active nucleosides 
is that they are not generally specific to the infected 
23 
cells. Floraphur (5-fluoro-1-tetrahydro-furyl-uracil) 
(9), 9-(hydroxy ethoxy methyDguanine tlO)/ Q-cyclohexyl-
25 6-propoxy adenine (11) are very active compounds, 
which are specific to the infected cells. These compounds 
(9-11) are not true nucleosides. 
H 
(X-
>N 
HN 
« 2 ^ ^ N > \ N ^C3H^0-^N 
HO 
10 11 
-44-
Although the heterocyclic moiety in these comp-
ounds is the same as present in the nucleosides of 
nucleic acids. However/ the aglycon part is not the 
usual D-ribose or D-deoxyribose sugars. The tetrahydro-
furyl, cyclohexyl, hydroxy ethoxy methyl moieties attac-
9 
hed at position N in these compounds due to their 
hydrophilic nature may be facilitating the transport 
of these molecules across the cell membrane. Inside 
the cell these compounds might be converted into ribo-
side by the action of ribo furanosyl transferase and 
to nuqlte^sides. 
2.2. PRESENT WORK 
The above reports prompted us to undertake 
the synthesis of alicyclic nucleosides of 4-hydroxy 
and 4-amino pyrazolo[3/4-d!] pyrimidines. In the present 
chapter the synthesis of l-[2-hydroxy-l-(hydroxy methyl) 
ethoxy]methyl-4( 5H)-oxo pyrazolo [ 3/4-d^ ] pyrimidine (23), 
4-amino-l-[2-hydroxy-l-(hydroxy methyl)ethoxy]methyl 
pyrazolo[pyrazolo[3,4-^]pyriraidine (25)/ l-[2-hydroxy-
l-(amino methyl)ethoxy]methy1-4(5H)-oxopyrazolo[3/4-
djpyrimidine (30)/ l-[2-hydroxy-l-(araino methyl)ethoxy] 
methyl-4-amino pyrazolo [ 3 / 4-d^ ] pyrimidine (34), l-[2-
hydroxy ethoxy )methyl]-4( 5H)-oxopyrazolo[3 ,4-dl] pyrimidine 
(38), 4-amino-l-[(2-hydroxy ethoxy)methyl]pyrazolo]3,4-
d^] pyrimidine (40) and their antileishmanial activity 
in vivo are reported, 
- 4 5 -
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14 
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s, 1 •N 
HO 1 0 
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23 26 
HO-i . 0 . 
30 
NH, 
HO—, 0 
ISfH, 
34 
HN 
^ 
HO- O 
38 
'N 
NH. 
N 
^ N-^ \ N - 'N 
HO O ^ 
40 
-46-
2.3 SYNTHESIS 
2.3.1 Synthesis of 4-methylthio pyrazolo[3,4-d]pyri-
midine (19) 
4-Methylthio py'razolo[3/4-d]pyrimidine (19) 
(Scheme 1) the key intermediate with synthesis of 4-
substituted-pyrazolo[3/4-^]pyrimidine nucleosides had 
13 
been synthesized following the method of Robins . Cond-
ensation of malononitrile (12) with triethylorthoformate 
(13) gave ethoxymethylene malononitrile (14) in quantit-
ative yield. Treatment of 1^ with hydrazin hydrate 
yielded 5-amino-4-cyanopyrazole (15) in 30% yield. 
Hydrolysis of _15^  with sulphuric acid afforded 5-araino-
pyrazole-4-carboxamide (16) in excellent yield. Cycli-
sation of 1^ with formamide gave 4(5H)-oxo-pyrazolo[3/4-
d]pyrimidine (17) in 58% yield. The mass spectrum, 
elemental analysis and the IR spectrum of 17 were in 
accordance with the assigned structure. Treatment of 
17 with P^Sc in refluxing pyridine yielded 4(5H)-thio-
pyrazolo[3,4-d]pyrimidine (18), which on methylation 
with methyliodide under basic conditions yielded 4-
methylthio pyrazolo[3,4-d]pyrimidine (19) in 52% overall 
yield. The pmr spectrum of 1^ had a singlet at S 2.4 
for the methylthio group and two singlets at 5>8-2 and 
S8.0 for H-6 and H-3 respectively. The mass spectrum 
of the compound had the base peak at m/z 167 (M^). Other 
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Reagents: (i) (CH2CO)20 ; (ii) NH2-NH2.H2O ; 
(iii) H,,SO^  ; (iv) HCO-NH2 ; (v) P2S5-C5H5N ; 
(vi) CH-^ l-NaOH 
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significant ions in the spectrum were at m/z 120 (C.H.N^) 
and 93 (C^H^N^). 
2.3.2 Synthesis of 1-[2-hydroxy-l-(hydroxymethyl) 
ethoxy]methyl-4(5H)-oxo-pyrazolo[3,4-d]pyrimi-
dine (23) 
Method-1 
Condensation of 4-methylthio pyrazolo[3,4-d^lpyri-
midine (19) (Scheme 2) with 1;3-dibenzyloxy-2-chloromethYl 
oxypropane (20) in the presence of Et_N gave l-[2-benzyl-
oxy-l-(benzyloxy methyl)ethoxy]methyl-4-methyIthio 
pyrazolo[3,4-^]pyrimidine (21) in 70% yield as an oil. 
The compund 22_ analysed for C-.H_^N.O_S and had molecular 
in peak at 450 (M ) in mass spectrum. PMR spectrum 
of compound 2_1^  had a singlet at S 5.88 for anomeric 
proton suggested the attachment of aglycon moiety. 
Compound 2JL ^ "^  reaction with NaOH gave 4(5H)-oxo deri-
vative (22). Hydrogenolysis of ^ with PdCl^ in H_ atmos-
phere furnished the required compound (23) in 55% yield. 
Compound ^ analysed for C^H,_N O, and had molecular ion 
peak at 240 (W ) in its mass spectrum. The ultra violet 
absorption of the compound 2^ ( A max 251/ 206 nm) . 
The site of alkylation in compound £3_ was established 
by correlating the UV absorption pattern with Table-
'1 . Compound ^ shows similar UV absorption pattern 
as allopurinol-1-riboside, reflecting 23 to be N-1 
SMe 
N CI 0 in i + V 
•N / ^ ^ 
H 
19 
Bn 
OBn 
20 
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SMe 
(i) 
21 
0 
1 
N 
OH 
23 
HN 
N 
17 
(iii) 
(vi) 
+ 20 
ReaqenLs: (i) DMF-Et^N ; (ii) NaOH-Dioxan 
(iii) PdCl2-H2 : liv) HMDS/(liH^)2^^4 * 
(V) CgH^ 
Scheme 2 
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Table 1; UV Absorption maxima of substituted pyrazolo 
[3/4-^]pyrimidine derivatives 
N-1-isomer 
Compd. 
No. 
A max (nm) 
pH. PH 11 
12. 
li 
ii 
42 
2 , 2 
CH OH 
-CH,-0-CH_-CH_-OH 
CH2-NH2 
-CH2-O-CH2-CH2-OH 
-Me 
-ribose 
251 
250 
270 
271 
250 
249 
252 
271 
270 
271 
N-2-isomer HN 
^ / ^ ,N> 
N' • ^ 
11 
44 
-Me 
-ribose 
255 
261 
280 
284 
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isomer. PMR spectrum of the compound 2_3 had two singlets 
at S7.95 and S7.9 for H-6 and H-3 respectively in the 
heterocyclic moiety. In the spectrum of 2J^  a two singlet 
at S 5.75 for anomeric proton suggested the attachment 
of aglycon moiety. 
Method-2 
The reaction of 4-hydroxY-pyrazolo[3;4-d]pyri-
(17) with hexamethyldisilazane (HMDS) in the pres.ence 
of (NH-)pSO. in a catalytic amount gave silylated deri-
vative (24). The condensation of the 2A^ (Scheme 2) 
with l/3-dibenzyloxy-2-chloromethyloxy propane (20) 
in refluxing benzene gave compound {22)i which on hydro-
genolysis with PdCl- furnished (23). The compound 23^ 
obtained by this procedure was identical in all respect 
with the compound made by Method-1. 
2.3.3 Synthesis of l-[2-hydroxy-l-(hydroxymethyl) 
ethoxy]methyl-4-aminopyrazolo[3/4-d]pyrimi-
dine (26) 
Condensation of 4-methylthio pyrazolo[3,4-
d^jpyrimidine (19) (Scheme 3) with ^ gave 21^ . Compound 
21 on reaction with anmonia under pressure at elevated 
temperature afforded (25) in 50% yield as an oil. Comp-
ound ^ analysed for C_-H-j-NcO- had a molecular ion peak 
at 419 (M ) in mass spectrum. PMR spectrum of the comp-
ound 25^ had a two proton singlets at S 5.8 for anomeric 
- 5 2 -
SMe 
N' 
+ 
N^ •N 
.N 
19 
SMe 
OBn 
N 
N 
BnO-lP\ 
cfen 
21 
S^  
( i i ) 
NH, 
N 
^ 
N 
N' 'N 
HO-
\ 
)H 
( i i i ) 
26 25 
R e a g e n t s : ( i ) DMF-Et^N ', ( i i ) MeOH-NH^ ; 
( i i i ) PdCl2-H2 *Bn = -CH2Ph 
Scheme 3 
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protons suggested the attachment of aglycon moiety. 
Compound25 on hydrogenolysis with PdCl„ in H„ atmosphere, 
furnished the required compound (26) in 40% yield. 
The compound ^ analysed for CgH,_N-0- had molecular ion 
peak at 239 (M ) in mass spectrum. In the infrared 
spectrum the N-H stretching was at 3100 cm . PMR spect-
rum of the compound ££ had a , singlet at S8.1 for H-
6and a singlet at £7.5 for H-3 of the heterocyclic 
moiety. For anomeric proton/ a singlet atS 5.7 suggested 
the attachment of aglycon moiety. 
2.3.4 Synthesis 1-[2-hydroxy-l-(aminomethyl)ethoxy] 
methyl-4(5H)-oxo-pyrazolo[3/4-^]pyrimidine (30) 
Condensation of bis{ triinethylsilyl) derivative 
of 4-hydroxy pyrazolo [3,4-(d] pyrimidine (24) (Scheme 
4) with 2-chloromethoxy-l-benzyloxy-3-phthaloylimidoprop-
27 
ane (27) in refluxing benzene gave 1-[2-benzyloxy-
l-(phthaloylimidomethyl)ethoxy]methyl-4(5H)-oxo-pyrazolo 
[3/4-d]pyrimidine (28). The pmr spectrum of the compound 
28 had a singlet at S8.5 for H-6 and S8.2 for H-3 in 
the heterocyclic moiety. While in the aglycon moiety 
it had a broad singlet at S 7.6-7.8 for 5H for Ar-H 
and for aromatic protons it had a oroad singlet at 
G7.3. Compound ^ had a singlet at S5.7 for anomeric 
protons suggested the attachment of aglycon moiety. 
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Scheme 4 
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The protecting phthaloyl group was removed 
by the reaction of ^ with hydrazin hydrate at O temp-
erature in EtOH to yield (29) in 40% yield as an oil. 
Which on debenzylation with PdCl_-H- afforded required 
compound (30) in 30% yield. Compound 3iO analysed for 
Cp,H,-N-O- had molecular ion peak at 239 (M ) in mass spe-
ctrum. The ultra violet absorption of the compound 
30 ( Amax 250/ 206 nm) shows the similar UV absorption 
pattern as in the case of allopurinol-1-riboside/ reflu-
cting 3£ to be N-1 isomer. PMR spectrum of the compound 
30 had two singlets at gS.O and $7.8 for H-6/ H-3 resp-
ectively for heterocyclic moiety and had a singlet 
at S5.8 for anomerdc .protons suggested the attachment 
of aglycon moiety. 
2.3.5 Synthesis of l-[2-hydroxy-l-(amirjiomethyl) ethoxy] 
methyl-4-amino pyrazolo[3/4-^]pYrimidine (34) 
Condensation of 4-amino pyrazolo [3,4-d^ ] pyri-
midine (31) (Scheme 5) 2-chloromethoxy-l-ben2yloxy-
3-phthaloylimido propane (27) in dry DMF gave l-[2-
benzyloxy-l-(phthaloylimidomethyl)ethoxy]methyl-4-amino 
pyrazolo[3/4-^]pyrimidine (32). The protecting phthaloyl 
group was removed by treatment of 3_2 at O with hydra-
zine hydrate to yield (33) as an oil in 40% yield. 
Debenzylation of _33. with PdCl^-H- atmosphere afforded the 
required compound (34) in 58% yield. The compound 34 
analysed for CgH, .N,0„ had molecular ion peak at 238 
•56-
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(iii)PdCt2-H2 
Scheme 5 
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(M +1). PMR spectrum had two singlets at g8.4 and 
{^ 8.1 for H-6 and H-3 respectively and also had a singlet 
at^5.9 for anomeric protons of aglycon moiety. 
2.3.6 Synthesis of l-(hydroxyethoxy)methyl-4(5H)-oxo-
pyrazolo[3/4-^]pyrimidine (38) 
Method-1 
Condensation of 4-methylthio pyjrazolo[3,4-d^]pyri-
midine (19) (Scheme 6) with benzoyloxy ethoxy methylene 
chloride in the presence of Et_N gave l-(benzoyloxyethoxy) 
methyl-4-methylthio pyrazolo[3,4-d]pyrimidine (36) 
in 60% yield. Deblocking of the protected nucleoside 
36 with methanolic ammonia at ambient temperature afford-
ed 3J_ in 55% yield. Treatment of _3Z Vith aq. KOH gave 
l-(hydroxyethoxy)methy1-4(5H)-oxo-pyrazolo[3;4-d]pyri-
midine (38) in 30% yield. Compound 38^  analysed for 
CgH, N.O- had molecular ion peak at m/z 210 (M ). Ultra 
violet absorption of the compound _38 ( A max 250.6, 
207.8 nm) suggested position N-1 the site of alkylation. 
PMR spectrum of the compound ^Q. had two singlets 
at &7.95 and ^7.9 for H-6 and H-3 respectively and 
a singlet atS5.7 for anomeric protons. 
Method-2 
ConderiiidLion o t 2A_ w i t h 3_b^  in r e t l u x i n g benzene 
gave l - ( b e n z o y l o x Y e t h o x y ) m e t h y l - 4 ( 5 H ) - o x o - p y r a z o l o [ 3 , 4 - 4 5 
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pyrimidine (39) in 58% yield. Treatment of ^ with 
methanolic NH_ furnished required compound (38). The 
compound 3£ obtained by thio procedure was identical 
in all respect with the compound made by the Method-1 
2.3.7 Synthesis of l-(hydroxyethoxy)methyl-4-amino 
pyrazolo[3/4-d]pyrimidine (40) 
Treatment of compound 37^  (Scheme 6) with 
NH^ at eluated temperature in a steel bomb gave l-(hyd-
roxyethoxy)methyl-4-amino pyrazolo[3 /4-d^ ] pyrimidine 
(40) in 50% yield. Compound 40 analysed for CnH,,Nc02had 
a molecular ion peak at 209 (M ) in mass spectrum. 
PMR spectrum of the compound had two singlets at S8.2 
and ^8.1 for H-6 and H-3 protons respectively and a 
singlet atS 5.7 for anomeric protons. 
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2.4 EXPERIMENTAL PROCEDURE 
Melting points were taken with Buchi capillary 
apparatus (silicon bath) and were uncorrected. UV 
spectra were recorded on a Perkin Eliner-202 spectropho-
tometer ( A max in nm) . IR spectra on a Perkin Elmer 
157 grating infracord (A max cm ). The PMR spectra were 
recorded on a Perkin Elmer 360L at 60 MHz (chemical 
shift £> scale). The compounds were routinely checked 
on silica gel plates and spots were 
under UV lamp or by iodine vapours or by spraying with 
10% sulphuric acid in ethanol followed by heating at 
100°C or by spraying with a mixture of p-anisaldehyde 
(2%) and sulphuric acid (10%) in ethanol followed by 
heating at 100°C. Evaporation of solution were carried 
out under reduced pressure with the bath temperature 
below 40°o. 
l-[2-Benzyloxy-l-(benzyloxymethyl)ethoxy]methyl-4-methyl 
thio pyrazolo[3,4-d]pyrimidine (23) 
located either 
A mixture of 4-methylthio pyrazolo[3/4-^]pyri-
midine (19) (3.o g, 18 mmol), DMF (30 ml) and Et^N (15 ml) 
was stirred at ambient temperature. To the mixture 
was added a solution of 1 /3-dibenzyloxy-2-chloromethoxy 
propane (20) (6.0 g, 18 mmol) in DMF (10 ml) and the 
mixture was stirred for 14 hr. The excess of reagent 
-el-
and solvent were removed at reduced pressure. The resi-
due was taken in EtOAC/ washed with H2O (2x100 ml)/ dried 
(Na_SO.) and the solvent removed. The product thus 
obtained was chromatographed on SiO„ column. Elution of 
t:ho column with CHCl^gave 2A_, as an oil (3.9 g, yield 
70%); MS (m/z): 450 (M"*"); PMR(CDCl2) : 8.7 (3, IH, H-6), 
7.9 (s, IH/ H-3), 7.2 (m, lOH, Ph-H) , 5.88 (s, 2H, 
H-1), 4.4-4.3 (each s, 4H, CH2Ph), 3.9 (m, IH, H-4')/ 
3.6-3.3 (m, 4H, H-3', H-5'), 2.6 (m, 3H, SCHg); (Found: 
C, 64.1; H/ 5.8; N, 12.5. C24H2gN^02S requires C, 64.1, 
H, 5.9; N, 12.5%.) 
l-[2-BenzYloxy-l-(benzyloxymethyl)ethoxy]methyl-4(5H)-
oxo-pyrazolo[3,4-d]pyrimidine (22) 
Method-1 
Compound 2^ (1.5 g, 3 mmol) in dioxane (30 
ml) was refluxed with aqueous 20% KOH (30 ml) for 12 
hr. The resulting mixture was cooled, neutralised with 
AcOH and the solvent removed under reduced pressure. 
The residue was taken in CHCl^, washed with water, dried 
(Na-SO.) and concentrated. The product thus obtained 
was chromatographed over Si02 column. Elution of the 
column with CHCl^iMeOH (96:4, v/v) gave (22) as an 
oil, (0.4 g, yield 30%); MS (m/z): 420 (M"*") ; IR(neat): 
1710 (C-0); PMR(CDCl2): 8.4 (s, IH, H-6), 8.1 (s, IH, 
H-3), 7.2 (m, lOH, PhH), 5.75 (s, 2H, H-1'), 4.4 (bs. 
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4H, H-3', 5'); 3.7-4.1 (m, IH, H-4')/ 3.3-3.5 (d, 4H, 
-OCH ); (Found: C, 65.76; H, 5.75; N, 13.3. C23H24N^O^ 
requires C, 65.8; H, 5.8; N, 13.5%). 
Method-2 
A mixture of pyrazolo[3/4-d] pyriniidine-4(5H)-
one (17) (2.0 q, 15 mmol), hexamethyldisilazane (8 
ml), dry toluene (50 ml) and (NH^)2S0^ (150 mg) was ref-
luxed for 24 hr. The excess of reagent and solvent 
from the resulting mixture were removed at reduced 
pressure to give 2_4/ which was used as such for further 
reaction 1,3-dibenzyloxy-2-chloromethyloxy propane 
(20) (6.0 q, 19 mmol) was added to ^ in dry benzene 
and refluxed for 12 hr. It was then cooled and filtered. 
The solvent from the filtrate was removed under reduced 
pressure. The residue was taken in CHCl-/ washed with aq, 
NaHCO (2x100 ml)/ set aq. NaCl solution (2x100 ml), 
H„0, dried (Na^SO.) and the solvent evaporated. The 
product thus obtained was chromatographed over Si02 col-
umn. Elution of the column with CHCl^cMeOH (96:4, v/v) 
gave (22) (1.1 g, yield 55%) as an oil. 
1- [ 2-Hydroxy-.l- ( hydroxymethy 1) ethoxy ] methy 1-4 (5H) -oxo-
pyrazolo[3,4-d]pyrimidine (23) 
A mixture of 2J^  (0.4 g, 95 mmol),' PdCl2 (50 mg) 
and MeOH (20 ml) was shaken in H_ atmosphere (45 lbs 
pressure) for 14 hr and filtered. The filtrate was 
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passed through ion exchange resin (lR-45/ OH form) and 
eluted with MeOH. The solvent from the eluate was removed, 
The product was chromatographed over SiO- column. Elution 
of the column with CHCl^tMeOH (80:20, v/v) afforded 
(23) (0.2 g, 55% yield); m.p.l62° (EtOH); MS (m/z): 240 
(M"^)T IR(KBr): 1680 (C=0) ; UV(MeOH) Amax: 251, 206; 
(NaOH): 270, 213; (Hcl): 250, 208; PMR(CDCl-+DMSO-d,): 
7.95 (s, IH, H-6) , 7.9 (s, IH, H-3) , 5.75 (s, 2H, H-
1'), 3.55-3.7 (m, IH, H-4'), 3.3-3.5 (m, 4H, H-3',5'); 
(Found: C, 40.0; H, 5.0; N, 23.3. ^QH^^^N^O. requires C, 
40.1; H, 5.2; N, 23.4%). 
l-[2-Benzyloxy-l-(benzyloxymethyl)ethoxy]methyl-4-amino 
pyrazolo[3,4-d]pyrimidine (25) 
Compound 2^ ^ (2.0 g, 4 mmol) and methanolic 
ammonia (25 ml) was heated in steel bomb at 110 C for 14 
hr. Solvent and excess of ammonia wfere removed and 
the residue were chromatographed on Si0„ column. Elution 
with CHCl^:Me0H (96:4, v/v) gave (25) as an oil (1 
gm, yield 50%); MS: 419 (M"^); PMR(CDCl2): 8.3 (s, IH, H-
6), 7.8 (s, IH, H-3), 7.3 and 7.2 (each s, 5H, Ar-fJ) , 
5.8 (s, 2H, H-1'), 4.5 and 4.4 (each s, 2H, -OCH2), 4.0 
(m, IH, H-4'), 3.7-3.3 (m, 4H, H-3', 5'); (Found: C, 
65.9; H, 6.0; N, 16.7 C23H25N5O2 requires C, 65.8; H, 
6.1; N, 16.8%). 
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1- [ 2-Hydroxy-l- (hydroxymethyl) ethoxy ] methyl-4-ainino 
pyrazolo[3/4-^]pyrimidine (26) 
Compound 2^ (0.8 g, 1.9 mmol), PdCl2 (100 mg) 
and MeOH (30 ml) was shaken in H» atmosphere (45 lbs 
pressure) for 14 hr and filtered. The filtrate was 
passed through ion exchange resin (IR-45/ 5H form) and 
eluted with MeOH. The solvent from the eluate was remo-
ved. The product was chromatographed over SiO„ column. 
Elution of the column with CHCl2:MeOH (80:20, v/v) aff-
orded (26) (0.3 g, yield 40%); m.p.l82°C; MS (m/z) 239 
(M"*"); IR(KBr): 3100 cm~^ (N-H); PMR(CDCl2+DMS0-dg) : 8.1 
(s/ IH, H-6), 7.5 (s, IH, H-3)/ 5.7 (s, 2H, H-1' ) / 
4.3 (m, IH, H-4')/ 3.1-3.5 (m, 4H, H-3', 5'); (Found: 
C, 45.2; H, 5.5; N, 29.3 CQH^2N503 requires C, 45.2; 
H, 5.6; N, 28.7%) . 
1-[2-Benzyloxy-l-(phthaloyliminomethyl)ethoxy]methyl-
4(5H)-oxo-pyrazolo[3,4-^]pyrimidine (28) 
A mixture of 24^  (3.0 g, 20 mmol) and 2-chloro-
methyloxy-l-benzyloxy-3-phthaloylimido propane (27) 
(9.0 g, 25 mmol)_ and dry benzene (150 ml) was stirred 
at ambient temperature for 2 hr and tnen refluxed for 
14 hr. The solvent from the resulting mixture was removed, 
The residue was taken in CHCl^, washed with NaHCO^ (2x 
150 ml), NaCl (2x100 ml), H2O, dried (Na2S0^) and the 
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solvent removed. The product thus obtained was chromato-
graphed over SiO^ column. Elution of the column with 
CHCl^rMeOH (98:2, v/v) gave (28), as an oil (2.5 g, 
yield 52%); MS (m/z): 459 (M"*"); PMR(CDCl2): 8.5 (s, IH/ 
H-6), 8.2 (s, IH, H-3), 7.6-7.8 (bs, 5H, Ar-H) , 7.3 
(bs, 4H, hr-H), 5.7 (s, 2H, H-1')/ 4.4 (s, 2H, -OCH^Ph)/ 
4.0-4.2 (m, IH, H-4')» 3.4-3.8 (m, 4H, H-3', H-5'). 
1-[2-Benzyloxy-1-(aminomethy1)ethoxy]methy1-4(5H)-oxo-
pyrazolo[3/4-d]pyrimidine (29) 
A mixture of 2£ (2.0 g, 4 mmol), MeOH (60 ml) 
and hydrazine hydrate (6 ml, 98%) was kept at O for 12 
hr. The solvent from the resulting mixture was removed 
at reduced pressure. The residue extracted with CHCl^ the 
solvent removed. The crude product was chromatographed 
over SiO- column. Elution of the column with CHCl-:MeOH 
(95:5, v/v) gave (29) as an oil, (0.8 g, yield 40%); 
MS (m/z): 329 (M"^); PMR(CDCl2): 8.2 (s, IH, H-6), 7.9 
(s, IH, H-3), 7.2 (s, 5H, Ar-IH) , 5.75 (s, 2H, H-1' ) / 
4.2 (s, 2H, -CH2Ph), 3.9-3.6 (m, IH, H-4'), 3.4-3.2 
(m, 4H, H-3', 5'). 
l-[2-Hydroxy-l-(aminomethyl)ethoxy]methy1-4(5H)-oxo-
pyrazolo[3,4-d]pyrimidine (30) 
A mixture of 29 (0.6 g, 1.8 mmol), MeOH (30 
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ml), PdCl_ (0.09 g) was shaken under H_ atmosphere (45 lbs 
pressure) for 12 hr and filtered. The filtrate was 
passed through ion exchange resin {IR-45/ OH form). The 
-solvent from the eluate was removed and the product 
was chromatographed over SiO_ column. Elution of the 
column with CHCl :MeOH (80:20, v/v) gave (30) (0.2 
g, yield 30%); m.p.202° (EtOH); MS (m/z): 239 (M"^) ; UV 
(MeOH) nm: 250, 206; (NaOH): 271.6, 211.8; (HCl): 250.2, 
207.2; PMR(CDCl-+DMSO-d^): 8.0 (s, IH, H-6), 7.8 (s, 
IH, H-3), 5.8 (s, 2H, H-1' ) , 3.0-2.5 (m, 4H, H-3' , 
5'), 2.6-2.4 (m, IH, H-4' ) ; (Found: C, 45.1; H, 5.5; 
N, 29.3 CgH^ '^^ s^Os requires C, 45.2; H, 5.4; N, 29.3%). 
l-[2-Benzyloxy-l-(phthaloylimidomethyl)ethoxylraethyl-
4-amino pyrazolo[3,4-d]pyrimidine (32) 
A mixture of 4-amino pyrazolo[3,4-^]pyrimidine 
(31) (2.0 g, 0.015 mmol), dry DMF (25 ml) and NaH (0.5 
g, 0.02 mmol) was stirred at ambient temperature for 
1 hr. To it was added 2-chloromethyloxy-l-benzyloxy-
3-phthaloylimidoglycerol (27) (8.0 g, 0.02 mmol) in 
dry DMF (15 ml) and stirred for 2 hr and then refluxed 
for 12 hr. Resulting mixture was cooled, H- was added and 
extracted with CHC1_, washed with H^O (2x150 ml), dried 
(Na^SO.) and concentrated iji vacuo. The crude product 
thus obtained was chromatographed over Si,0- column. Elut-
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ion of the column with CHClo:MeOH (98:2, v/v) gave 
(32) as an oil (1.9 g, yield 55%); MS (m/z): 458 (M"^); 
PMR(CDCl3): 8.0 (s, IH, H-3) , 7.7 (s, IH, H-6) , 7.25 
(s, 5H, Ar-H) , 7.4-7.6 (d, 4H, Ar-1«) , 5.6 (s, 2H, H-
1')/ 4.9 (s, 2H, -0-CH2Ph)' 4.1-4.3 (m, IH, H-4' ) / 
3.4-3.6 (m, 4H, H-3' , 5')• 
l-[2-Benzyloxy-l-(aniinomethyl)ethoxy]methyl-4-amino 
pyrazolo[3/4-d]pyrimidine (33) 
A mixture of _32. (1-2 9/ 0.003 mmol), MeOH (50 
ml) and hydrazin hydrate (5 ml/ 0.1 mmol) was kept 
at O°for 12 hr. The solvent and excess of reagent were 
removed under reduced pressure. The residue was taken 
in CHCl^ (50 ml) and concentrated. The crude product 
thus obtained was chromatographed over SiO- column. Elut-
ion of the column with CHCl^rMeOH (95:5) gave (33) 
as an oil (0.5 g, yield 40%); MS (m/z): 328 (M^); PMR 
(CDCl^+DMSO-dg) : 8.25 (s, IH, H-6), 8.15 (s, IH, H-
3), 7.2 (s, 5H, Ar-H), 5.8 (s, 2H, H-1')/ 4.35 (s, 
2H, -CH^2Ph), 4.1-4.3 (m, IH, H-4'), 3.5-3.6 (m, 4H, 
H-3', 5'); (Found: C, 58.5; H, 6.1; N, 25.6 C^gH2QNg02 
requires C, 58.6; H, 6.3; N, 25.7%). 
1-[2-Hydroxy-l-(aminomethyl)ethoxy]methyl-4-amino pyra-
zolo[3,4-d]pyrimidine (34) 
A mixture of 22 (0.4 g, 1.2 mmol) and PdCl-
•68-
(60 mg)/ MeOH (25 ml) Wrj.j shaken at 45 lbs pressure 
under H- atmosphere. The catalyst was filtered/ and 
the filtrate was neutralised with resin (IR-45/ OH form) 
and the solvent removed. The crude product thus obta-
ined was chromatographed over SiO- column. Elution of 
the column with CHCl^rMeOH (80:20, v/v) afforded (34) 
(0.2 g, yield 58%), as an oil; MS (m/z) : 238 (M"*" +1); PMR 
(CDCl^+DMSO-dg) : 8.4 (s, IH, H-6) , 8.1 (s, IH, H-3) , 
5.9 (s, 2H, H-1')/ 4.0-4.5 (m, IH, H-4')/ 3.6-3.8 (d, 
I 
4H, H-3', 5')/ 5.0 (bs, 2H, N-H); (Found: C, 45.4; 
H, 5.4; N, 35.3 CgHj^^N^O^ requires C, 45.6; H, 5.8; 
N, 35.4%). 
l-[Benzoyloxyethoxy]methyl-4-methylthio pyrazolo[3,4-
d]pyrimidine (36) 
To a stirring mixture of 1^ (3.0 g, 18 mmol), 
Et_N (20 ml) and dry DMF (50 ml) was added dropwise 
a solution of benzoyloxyethoxy methyl chloride (6.0 
g, 28 mmol) [prepared by passing dry HCl gas into para-
formaldehyde and l-benzoyloxy-2-hydroxy ethane mixture 
in dry CH2CH2 at 0 for 2 hr] and stirring continued 
for 15 hr. The solvent and excess of reagent were rem-
oved at reduced pressure. The residue was extracted 
with CHCl^ , washed with H-O, dried (Na SO ) and conce-
ntrated in vacuo. The product thus obtained was chromato-
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graphed over SiO„ column. Elution of the column with 
CHCl^ gave (36) as an oil (2.2 g, yield 60%); MS (m/z); 
344 (M"^); PMR(CDCl2): 8.65 (s, IH, H-6) , 7.7-8.1 (s, 
2H, Ar-H) , 7.1-7.5 (s, 3H, Ar-H) , 5.85 (s, 2H, H-1' ) . 
4.1-4.4 (m, 2H, H-3' ) , 3.6-3.9 (m, 2H, H-4')/ 2.6 (s, 
3H, -SCH_); (Found: C, 55.8; H, 4.7; N, 16.3 C,^H.^N,0-S 
—^ ib io b 5 
requires C, 55.7; H, 4.7; N, 16.4%). 
l-[Hydroxyethoxy]methYl-4-methylthio pyrazolo[3/4-^] 
pyrimidine (37) 
A mixture of ^^ (2.0 g, 6 mmol) and methanolic 
NHg (45 ml, MeOH at 0° saturated with NH^) was kept at 
ambient temperature for 24 hr. The solvent and excess 
of reagent from the result. ir\g mixture were removed 
and the residue was chromatographed over SiO„ column. 
Elution of the column with CHCl2:MeOH (96:4, v/v) affor-
ded (37) (1.1 g, yield 55%); m.p.94°; MS (m/z): 240 (M"^) ; 
IR(KBr): 3336 (0-H); PMR(CDCl2+DMS0-dg): 8.8 (s, IH, H-6); 
8.5 (s, IH, H-3), 5.8 (s, 2H, H-1 ' ) , 3.6 (bs, 4H, H-
3', 4')/ 2.6 (s, 3H, -SCH^): (Found: C, 45.0; H, 5.0; 
N, 23.3 *^ 9f^ i2'^ 4°2^  requires C, 45.1; H, 5.2; N, 23.3%). 
1- [Hydroxyethoxy ]methyl-4( 5H)-oxo-pyrazolo[3 ,4-d^ ] pyri-
midine (38) 
Method-1 
Compound 37 (0.5 g, 2 mmol) in dioxane (60 ml) 
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was refluxed with aqueous KOH (20%, 15 ml) for 12 hr. 
The resulting ixture was cooled/ neutralized with acetic 
and the solvent removed at reduced pressure. The resi-
due was extracted with CHCl-/ washed with H^O/ dried 
(Na^SO.) and concentrated. The crude product thus obt-
ained was chromatographed over SiO^ column. Elution of 
the column with CHCl^iMeOH (90:10, v/v) gave (38) (0.2 
g, yield 30%), crystallized in EtOH; m.p.138-40°; UV 
(MeOH): 250.6, 207.8; (NaOH): 221.2, 215.2; (HCl): 
250.8, 212.6; MS (m/z) : 210 (M"*"); PMR(CDCl2+DMS0-dg: 
7.95 (s, IH, H-6), 7.9 (s, IH, H-3), 5.7 (s, 2H, H-
1'), 3.5 (bs, 4H, H-3', 4'); (Found: C, 45.7; H, 4.8; 
N, 26.6 CQH^QN^O^ requires C, 45.8; H, 4.9; N, 26.6%). 
Method-2 
A mixture of 3^ (0.8 g, 2.5 mmol) and methanolic 
ammonia (25 ml, methanol at O saturated with NH-) was 
kept for 24 hr at ambient temperature. The solvent 
and excess of NH_ were removed at reduced pressure. 
The crude product thus obtained was chromatographed 
over SiO^ column. Elution of the column with CHCl_:MeOH 
(92:8, v/v) gave (38) (0.5 g, yield 60%), m.p.138-40°. 
l-[Benzoyloxy ethoxy]methyl-4(5H)-oxo-pyrazolo[3,4-
dlpyrimidine (39) 
The compound 2£ (3.0 g, 20 mmol) in C^Hg (40 ml) 
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was refluxed with l-benzoyloxy-2-chloromethoxy ethane 
(35) (6.0 q, 28 mmol) for 16 hr. The resulting mixture 
was cooled/ filtered. The solvent from the filtrate 
was removed. The residue extracted with CHC1_/ washed 
with NaHCO-/ H„0/ dried (Na„SO.) and concentrated. 
The product thus obtained was chronatographed over 
SiO column. Elution of the column with CHCl2:MeOH (98:2, 
v/v) gave (39) (1.7 g, yield 58%); m.p.118-19° (EtOH); 
MS (m/z): 314 (M"*"); UV: 1710 (C=0) ; PMR(CDCl2) : 8.25 and 
8.1 (each s, 2H, H-6, H-3), 8.0-7.8 (m, 2H, Ar-tt adjacent 
to C=0)/ 7.45-7.25 (m, 3H/ hr-E) , 5.5 (s, 2H, H-1' ) / 
4.5-4.3 (m, 2H, H-3')/ 4.1-3.8 (m, 2H, H-4'); (Found: 
C, 57.3; H, 4.8; N, 17.9 C^^H^^N^G^ requires C, 57.4; 
H, 4.5; N, 17.7%). 
l-[Hydroxyethoxy ]methyl-4-amino pyrazolo[3 /4-d^ ] pyrimi-
dine (40) 
A mixture of 31_ (0.5 g, 21 mmol) and methanolic 
NH^ (20 ml/ MeOH at 0° saturated with NH^) was heated in 
a steel bomb at 110 for 14 hr. The solvent and excess 
of NH_ from the resulting mixture were removed at red-
uced pressure. The product thus obtained was chromato-
graphed over SiO_ column. Elution of the column with 
CHCl2:MeOH (90:10, v/v) gave (40) (0.3 g, yield 50%); 
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m.p.153-154° (EtOH); MS (m/z): 209 (M"*") ; PMR(CDC1- + 
DMSO-dg): 8.2 (s, IH, H-6) , 8.1 (s, IH, H-3) , 5.7 (s, 
2H, H-1')/ 3.6 (s, 4H, H-3', 4'); (Found: C, 45.9; 
H, 5.3; N, 33.5 <^ QH3^ 3^ Ng02 requires C, 45.8; H, 5.3; 
N, 33.7%). 
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2.5 BIOLOGICAL ACTIVITY 
Antileishmanial Activity 
Antileishmanial activity (iji vivo) of the nucl-
oonidofi aqainfi^ amastiqotoa of r.oi nhmnnia donovani 
was determined in hamsters infected with Dd-8 strain 
according to the procdure described earlier . Allopuri-
nol (17) was used as a standard.drug. 
The activity of the compounds (Series A) is 
given in Table 2. 1/5-Dihydro-4H-pyrazolo[3,4-c[]pyrimi-
dine-4-one (allopurinol)(17) exhibited 88% inhibition 
at 25 mg/kg dose on the 7th day. Substitution of (2-
hydroxyethoxy)methyl function which represented (1'-
C.'-C^ ') chain of ribose at N, of heterocyclic moiety 
asin (38) rendered the compound inactive. Introduction 
of [2-hydroxy-l-(hydroxymethyl)ethoxy] function which 
represented C, '-(3'-C^'-C^ ') of ribose lat N, as in (23) 
considerably increased the activity (75%). The activity 
was reduced drastically when the hydroxy functioij at 
2 of - [2-hydroxy-l-(hydroxymethyl)ethoxy] group was 
replaced by an amino function as in (30). The data 
thus suggested that not only the nature and chain length 
of glucone moiety at N-1 is critical for antileish-
manial activity of the alicyclic nucleosides (Series 
A) but also the nature of the functional groups present 
in it. 
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The antileishmanial activity of nucleosides, 
(Series B) is recorded in Table 2. The activity of 
the nucleoside (40) was considerably decreased when 
(2-hydroxyethoxy)methyl function was introduced at 
N, of heterocyclic moiety. However when the hydroxy 
group in the nucleoside (40) was protected with benzoyl-
oxy function; the corresponding nucleoside (39) exhibited 
a high order of activity. The compound (26) became 
inactive when the hydroxy function at C- of - [2-hydroxy-
l-(hydroxymethyl)ethoxy] moiety was replaced by an 
amino function. The antileishmanial activity in the 
Series B type of alicyclic nucleosides, thusi revealed 
that the nature and chain length and also the nature 
of the functional group are critical for the activity. 
Further the high order of activity of the blocked nucleo-
side (39) indirectly suggested that the compound is 
probably an inhibitor of some important enzyme involved 
in the purine salvage process of the parasites. 
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Table 2 Antileishmanial Activity (j^ vivo) of the 
nucleosides (Series A and B) at 25 mg/kg 
on 7th day/ against Amastigotes of Leishmania 
Series A 
donovani in hamster. 
HN 
A 
^ N' ^ 
Compd. 
No. 
R Inhibition 
(%) 
11 
li 
30 
H 88 
-CH2-O-CH2-CH2-OH 0 
-CH2-0-CH2-CH2-0-CO-Ph 82 
-CH_-0-CH-CH„OH 75 
CH2OH 
-CH2-O-CH-CH2OH 15 
CH2-NH2 
Series B 
m. 
N 
k ^ 
40 
26 
-CH2-O-CH2-CH2-OH 
-CH2-O-CH-CH2OH 
25 
O 
CH2OH 
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